Metabolomics approach reveals key plasma biomarkers in multiple myeloma for diagnosis, staging, and prognosis.

ABSTRACT:

Background

Multiple myeloma (MM) is the most aggressive and prevalent primary malignant tumor within the blood system, and can be classified into grades RISS-I, II, and III. High-grade tumors are associated with decreased survival rates and increased recurrence rates. To better understand metabolic disorders and expand the potential targets for MM, we conducted large-scale untargeted metabolomics on plasma samples from MM patients and healthy controls (HC).

Methods

Our study included 33 HC, 38 newly diagnosed MM patients (NDMM) categorized into three RISS grades (grade I: n = 5; grade II: n = 19; grade III: n = 8), and 92 MM patients post-targeted therapy with bortezomib-based regimens. Simultaneously, MM cell lines were employed for validation studies. Metabolites were anal

SUBMITTER: Wang X 

PROVIDER: S-EPMC11800462 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature